Effect of Eriocitrin Supplementation in Subjects With Intermediate Hyperglycemia

Overview

First, it will be evaluated whether supplementation of eriocitrin reduces hyperglycemia and insulin resistance, significantly reducing the risk of diabetes. The effects of eriocitrin on the lipid profile, inflammatory, endothelial, hepatic and renal biomarkers will also be evaluated. It is expected that metabolic parameters that constitute risk factors for diabetes and associated chronic diseases are expected to be improved by supplementation with eriocitrin

Full Title of Study: “Evaluation of Metabolic Parameters in Subjects With Intermediate Hyperglycemia Supplemented With Eriocitrin: A Parallel, Double-blind, Randomized, Placebo-controlled Clinical Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: February 28, 2018

Detailed Description

Volunteers will be invited to appear in a 12-hour fast to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview to confirm eligibility according to the inclusion and exclusion criteria. The collection of blood and the glycemic curves will be carried out next to a Laboratory of Clinical Analyzes, commercial, based in the city of Araraquara. The sample number took into account variances on glycated hemoglobin with a type I error α = 0.05 and a type II error β = 0.2 (80% power) (Mohammad, 2015). The minimum sample size considering an approximately 20% dropout rate, should have 20 individuals per group. In order to ensure adequate nutrition for the nutritional and energetic needs of volunteers, an individual food plan shall be prescribed, calculated according to the DRI equations. The volunteer will be asked to complete the Food Record for three days at the 3rd, 5th, 7th, 9th and 11th week. Data analysis of energy intake, macronutrients and micronutrients will be performed through the DietBox® . The anthropometric measurements will be performed before the intervention and in the 3rd, 5th, 7th, 9th and 11th week by Nutritionist. Four samples of 30mL of fasting blood each will be obtained before the intervention, in the 4th, 8th and 12th week in the Laboratory of Clinical Analyzes. The blood will be centrifuged to obtain the serum, which will be frozen at -80 ° C until subsequent biochemical analyzes. Normality and homogeneity will be evaluated by Shapiro-Wilk test and Levine tests, respectively. The T test will be used to compare baseline time between groups. The two-way repeated-measures ANOVA will be used to compare changes within and between the eriocitrin and control groups over the 12-week period. P significant at ≤ 0.05.

Interventions

  • Dietary Supplement: Eriocitrin
    • The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
  • Other: Placebo
    • The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.

Arms, Groups and Cohorts

  • Experimental: Group A
    • Individuals will receive a dose of 140 mg / d eriocitrin for 12 weeks
  • Experimental: Group B
    • Individuals will receive a dose of 280 mg / d eriocitrin for 12 weeks
  • Experimental: Group C
    • Individuals will receive a dose of 560 mg / d eriocitrin for 12 weeks
  • Placebo Comparator: Group D
    • Individuals will receive the placebo with corn starch excipient for 12 weeks

Clinical Trial Outcome Measures

Primary Measures

  • Glucose
    • Time Frame: 12 Weeks
    • mg/dL

Secondary Measures

  • glycated hemoglobin
    • Time Frame: 12 Weeks
    • percentage
  • insulin
    • Time Frame: 12 Weeks
    • µU/mL
  • Cholesterol
    • Time Frame: 12 Weeks
    • mg/dL
  • triglycerides
    • Time Frame: 12 Weeks
    • mg/dL
  • HDL-C
    • Time Frame: 12 Weeks
    • mg/dL
  • LDL-C
    • Time Frame: 12 Weeks
    • mg/dL
  • TNF-alpha
    • Time Frame: 12 Weeks
    • pg.mL
  • Interleucina 6
    • Time Frame: 12 Weeks
    • pg.mL
  • c-reactive protein
    • Time Frame: 12 Weeks
    • mg/dL
  • aspartate aminotransferase
    • Time Frame: 12 Weeks
    • U/L
  • alkaline phosphatase
    • Time Frame: 12 Weeks
    • U/L
  • Gamma-Glutamyl Transferase
    • Time Frame: 12 Weeks
    • U/L
  • alanine aminotransferase
    • Time Frame: 12 Weeks
    • U/L

Participating in This Clinical Trial

Inclusion Criteria

  • Glycemia of 6.1 to 7.0 mmol / L – Glycated hemoglobin with values between 5.7 and 6.4% Exclusion Criteria:

  • use of drugs, vitamins and dietary supplements, alcohol consumption (> 20 g alcohol/d), and intense physical activity (> 5 hours/week). – History of cardiovascular disease, diabetes mellitus, liver or kidney disease

Gender Eligibility: All

Minimum Age: 30 Years

Maximum Age: 59 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Thais Cesar
  • Collaborator
    • Ingredients by Nature TM
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Thais Cesar, Principal Investigator – São Paulo State University
  • Overall Official(s)
    • Thais B Cesar, Ph.D, Principal Investigator, Sao Paulo State University “Julio de Mesquita Filho”, Faculdade de Ciências Farmacêuticas

References

Mohammad M, et al. Effects of Hesperidin Supplementation on Glycemic Control, Lipid Profile and Inflammatory Markers in Patients with Type 2 Diabetes: A Randomized Double Blind Placebo Control Clinical Trial. Research Article, Acta Biologica Indica 2015, 4(1):75-83. ISSN 2279-0160

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.